1. Home
  2. LXRX vs POLE Comparison

LXRX vs POLE Comparison

Compare LXRX & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • POLE
  • Stock Information
  • Founded
  • LXRX 1995
  • POLE 2024
  • Country
  • LXRX United States
  • POLE United States
  • Employees
  • LXRX N/A
  • POLE N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • POLE
  • Sector
  • LXRX Health Care
  • POLE
  • Exchange
  • LXRX Nasdaq
  • POLE NYSE
  • Market Cap
  • LXRX 283.7M
  • POLE 296.0M
  • IPO Year
  • LXRX 2000
  • POLE 2024
  • Fundamental
  • Price
  • LXRX $0.71
  • POLE $10.08
  • Analyst Decision
  • LXRX Buy
  • POLE
  • Analyst Count
  • LXRX 2
  • POLE 0
  • Target Price
  • LXRX $4.00
  • POLE N/A
  • AVG Volume (30 Days)
  • LXRX 4.1M
  • POLE 3.6K
  • Earning Date
  • LXRX 03-10-2025
  • POLE 01-01-0001
  • Dividend Yield
  • LXRX N/A
  • POLE N/A
  • EPS Growth
  • LXRX N/A
  • POLE N/A
  • EPS
  • LXRX N/A
  • POLE N/A
  • Revenue
  • LXRX $5,229,000.00
  • POLE N/A
  • Revenue This Year
  • LXRX $842.94
  • POLE N/A
  • Revenue Next Year
  • LXRX $19.76
  • POLE N/A
  • P/E Ratio
  • LXRX N/A
  • POLE N/A
  • Revenue Growth
  • LXRX 886.60
  • POLE N/A
  • 52 Week Low
  • LXRX $0.62
  • POLE $9.94
  • 52 Week High
  • LXRX $2.83
  • POLE $11.16
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 43.33
  • POLE N/A
  • Support Level
  • LXRX $0.66
  • POLE N/A
  • Resistance Level
  • LXRX $0.97
  • POLE N/A
  • Average True Range (ATR)
  • LXRX 0.07
  • POLE 0.00
  • MACD
  • LXRX -0.00
  • POLE 0.00
  • Stochastic Oscillator
  • LXRX 16.13
  • POLE 0.00

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

Share on Social Networks: